









Markets
/
Stocks
/
nasdaq-bcyc
/

Bicycle Therapeutics PLC

BCYC

4.330USD

-0.170-3.78%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

216.20MMarket Cap

LossP/E TTM



Bicycle Therapeutics PLC

4.330

-0.170-3.78%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Bicycle Therapeutics PLC

Currency: USD Updated: 2026-03-27

Key Insights

Bicycle Therapeutics PLC's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 68 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.91.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Bicycle Therapeutics PLC's Score

Industry at a Glance

Industry Ranking

68 / 391

Overall Ranking

178 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Bicycle Therapeutics PLC Highlights

StrengthsRisks

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 169.08% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 72.59M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 72.59M.

Overvalued

The company’s latest PE is -1.36, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 39.22M shares, increasing 0.08% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 10.09K shares of this stock.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

12.909

Target Price

+186.87%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Bicycle Therapeutics PLC is 6.84, ranking 182 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 47.95M, representing a year-over-year increase of 1193.28%, while its net profit experienced a year-over-year increase of 61.13%.

Score

Industry at a Glance

Previous score

6.84

Change



Financials

9.30

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.90

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.85

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.05

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.09

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Bicycle Therapeutics PLC's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Bicycle Therapeutics PLC is 7.66, ranking 91 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.36, which is -3.37% below the recent high of -1.32 and -516.64% above the recent low of -8.41.

Score

Industry at a Glance

Previous score

7.66

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 68/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Bicycle Therapeutics PLC is 7.86, ranking 263 out of 391 in the Biotechnology & Medical Research industry. The average price target is 16.00, with a high of 44.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

7.86

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

12.909

Target Price

+199.51%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Bicycle Therapeutics PLC

BCYC

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Bicycle Therapeutics PLC is 5.38, ranking 316 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 5.30 and the support level at 3.78, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.57

Change

-0.19

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.051

Sell

RSI(14)

33.024

Neutral

STOCH(KDJ)(9,3,3)

16.560

Neutral

ATR(14)

0.308

High Vlolatility

CCI(14)

-100.799

Sell

Williams %R

94.215

Oversold

TRIX(12,20)

-0.953

Sell

StochRSI(14)

41.602

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

4.466

Sell

MA10

4.605

Sell

MA20

4.961

Sell

MA50

5.599

Sell

MA100

6.220

Sell

MA200

6.970

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Bicycle Therapeutics PLC is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 114.58%, representing a quarter-over-quarter decrease of 9.44%. The largest institutional shareholder is PRFDX, holding a total of 1.17M shares, representing 2.33% of shares outstanding, with 27.55% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Baker Bros. Advisors LP

10.89M

Forbion Capital Partners

3.45M

Armistice Capital LLC

2.98M

+6.36%

Invus Public Equities Advisors, LLC

2.01M

Acadian Asset Management LLC

1.31M

+88.20%

Long Focus Capital Management LLC

1.42M

+7.70%

Candriam Luxembourg S.A.

1.35M

+0.05%

Candriam Belgium S.A.

1.17M

T. Rowe Price Associates, Inc.

Star Investors

1.38M

-5.69%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Bicycle Therapeutics PLC is 4.00, ranking 109 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.67. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.